Cheryl Ho

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 29

Top Venues

Current oncology (Toronto, Ont.)

JCO oncology practice

JCO precision oncology

BMC cancer

BC Cancer

This page only lists publications with an associated author ORCID identifier.

Affiliation History

BC Cancer

Canada

Medical oncologist :: Medical Oncology

Publications

Samantha Pollard, Morgan Ehman, Anna Hermansen, Deirdre Weymann, Emanuel Krebs, Cheryl Ho, Howard J Lim, Steven J M Jones, Yvonne Bombard, Timothy P Hanna, Chiquita Hessels, Holly Longstaff, Robert M Cook-Deegan, Tania Bubela, Deirdre Weymann
"I Just Assumed This Was Already Being Done": Canadian Patient Preferences for Enhanced Data Sharing for Precision Oncology. JCO precision oncology 8 (2024)
Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina K Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current oncology (Toronto, Ont.) 30 (6) (2023)
Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina K Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current oncology (Toronto, Ont.) 30 (6) (2023)
Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina K Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current oncology (Toronto, Ont.) 30 (6) (2023)
Marie-Hélène Denault, Jamie Feng, Shelley Kuang, Aria Shokoohi, Bonnie Leung, Mitchell Liu, Eric Berthelet, Janessa Laskin, Sophie Sun, Tina Zhang, Cheryl Ho, Barbara L Melosky
Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression. Current oncology (Toronto, Ont.) 30 (8) (2023)
Ali Silver, Cheryl Ho, Qian Ye, Jianjun Zhang, Ian Janzen, Jessica Li, Montgomery Martin, Lang Wu, Ying Wang, Stephen Lam, Calum MacAulay, Barbara L Melosky, Ren Yuan
Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years. Current oncology (Toronto, Ont.) 30 (6) (2023)
Ali Silver, Cheryl Ho, Qian Ye, Jianjun Zhang, Ian Janzen, Jessica Li, Montgomery Martin, Lang Wu, Ying Wang, Stephen Lam, Calum MacAulay, Barbara L Melosky, Ren Yuan
Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years. Current oncology (Toronto, Ont.) 30 (6) (2023)
Kelly Li, Ian Bosdet, Stephen Yip, Cheryl Ho, Janessa Laskin, Barbara L Melosky, Ying Wang, Sophie Sun
Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer. Current oncology (Toronto, Ont.) 30 (8) (2023)
Ali Silver, Cheryl Ho, Qian Ye, Jianjun Zhang, Ian Janzen, Jessica Li, Montgomery Martin, Lang Wu, Ying Wang, Stephen Lam, Calum MacAulay, Barbara L Melosky, Ren Yuan
Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years. Current oncology (Toronto, Ont.) 30 (6) (2023)
Ali Silver, Cheryl Ho, Qian Ye, Jianjun Zhang, Ian Janzen, Jessica Li, Montgomery Martin, Lang Wu, Ying Wang, Stephen Lam, Calum MacAulay, Barbara L Melosky, Ren Yuan
Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years. Current oncology (Toronto, Ont.) 30 (6) (2023)
Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina K Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current oncology (Toronto, Ont.) 30 (6) (2023)
Rebekah Rittberg, Bonnie Leung, Zamzam Al-Hashami, Cheryl Ho
Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization. Current oncology (Toronto, Ont.) 29 (12) (2022)
Roy Avraham Hilzenrat, Stephen Yip, Barbara L Melosky, Cheryl Ho, Janessa Laskin, Sophie Sun, James J Choi, Anna L McGuire
Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study. Current oncology (Toronto, Ont.) 30 (1) (2022)
Roy Avraham Hilzenrat, Stephen Yip, Barbara L Melosky, Cheryl Ho, Janessa Laskin, Sophie Sun, James J Choi, Anna L McGuire
Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study. Current oncology (Toronto, Ont.) 30 (1) (2022)
Rebekah Rittberg, Bonnie Leung, Zamzam Al-Hashami, Cheryl Ho
Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization. Current oncology (Toronto, Ont.) 29 (12) (2022)
Rebekah Rittberg, Bonnie Leung, Zamzam Al-Hashami, Cheryl Ho
Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization. Current oncology (Toronto, Ont.) 29 (12) (2022)
Roy Avraham Hilzenrat, Stephen Yip, Barbara L Melosky, Cheryl Ho, Janessa Laskin, Sophie Sun, James J Choi, Anna L McGuire
Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study. Current oncology (Toronto, Ont.) 30 (1) (2022)
Roy Avraham Hilzenrat, Stephen Yip, Barbara L Melosky, Cheryl Ho, Janessa Laskin, Sophie Sun, James J Choi, Anna L McGuire
Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study. Current oncology (Toronto, Ont.) 30 (1) (2022)
Rebekah Rittberg, Bonnie Leung, Zamzam Al-Hashami, Cheryl Ho
Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization. Current oncology (Toronto, Ont.) 29 (12) (2022)
Bonnie Leung, Selina K Wong, Cheryl Ho
End-of-Life Health Resource Utilization for Limited English-Proficient Patients With Advanced Non-Small-Cell Lung Cancer. JCO oncology practice 18 (10) (2022)
Rebekah Rittberg, Bonnie Leung, Zamzam Al-Hashami, Cheryl Ho
Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization. Current oncology (Toronto, Ont.) 29 (12) (2022)
Roy Avraham Hilzenrat, Stephen Yip, Barbara L Melosky, Cheryl Ho, Janessa Laskin, Sophie Sun, James J Choi, Anna L McGuire
Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study. Current oncology (Toronto, Ont.) 30 (1) (2022)
Roy Avraham Hilzenrat, Stephen Yip, Barbara L Melosky, Cheryl Ho, Janessa Laskin, Sophie Sun, James J Choi, Anna L McGuire
Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study. Current oncology (Toronto, Ont.) 30 (1) (2022)
Roy Avraham Hilzenrat, Stephen Yip, Barbara L Melosky, Cheryl Ho, Janessa Laskin, Sophie Sun, James J Choi, Anna L McGuire
Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study. Current oncology (Toronto, Ont.) 30 (1) (2022)
Cheryl Ho, Brandon Chan, David Cameron, Aria Shokoohi, Deirdre Weymann, Howard J Lim
Readiness of Healthcare Systems to Generate Real-World Evidence: Reliability of CT Radiographic End Points for Evaluation of First-Line Systemic Treatment. JCO oncology practice 17 (12) (2021)
Selina K Wong, Jeremy Hamm, Aria Shokoohi, Colleen E McGahan, Cheryl Ho
Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment. BMC cancer 21 (1) (2021)
M Soleimani, C Kollmannsberger, A Bates, B Leung, Cheryl Ho
Patient-reported psychosocial distress in adolescents and young adults with germ cell tumours. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 29 (4) (2020)
Sara Moore, Bonnie Leung, Jonn Wu, Cheryl Ho
Population-based analysis of curative therapies in stage II non-small cell lung cancer: the role of radiotherapy in medically inoperable patients. Radiation oncology (London, England) 15 (1) (2020)
Amirrtha Srikanthan, Bonnie Leung, Aria Shokoohi, Alannah M Smrke, Alan Bates, Cheryl Ho
Psychosocial Distress Scores and Needs among Newly Diagnosed Sarcoma Patients: A Provincial Experience. Sarcoma 2019 (2019)

Cheryl Ho.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Cheryl Ho